title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 538
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

status: Public on Dec 21 2025

type: SRA

city: Boston

first: Jonathan

middle: Andrew

last: Nowak

state: MA

address: 75 Francis St.

department: Pathology

country: USA

institute: Brigham and Women's Hospital

description:
Library name: Sample 514
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

library_source: transcriptomic

data_processing:
GeoMx DSP data were pre-processed using the GeoMxTools package (version 3.8.0) in R. DCC files containing raw count data from NGS, the PKC file pertaining to the GeoMx Human WTA, and a custom-made annotation file derived from the FASTQ lab worksheet files were condensed into an object of the GeoMxSetObject class. The GeoMxSetObject contained a total of 716 areas of illumination (AOIs) prior to quality control. AOIs were excluded from further analysis based on read metrics, sequencing saturation, and nuclei count. Probes were excluded from further analysis based on count distribution across AOIs and an outlier test and were then condensed into a gene-level count matrix. Next, all AOIs with at least 1% of genes detected and all genes detected in at least 1% of AOIs were retained in the dataset. After these quality control steps, a total of 676 AOIs remained in the dataset. Batch correction was then performed using the ComBat-Seq algorithm as implemented in the sva R package (3.52.0). Finally, count data were normalized to the third quantile and log2-transformed for downstream analysis.
AOIs were excluded from further analysis based on read metrics, sequencing saturation, and nuclei count.
Probes were excluded from further analysis based on count distribution across AOIs and an outlier test and were then condensed into a gene-level count matrix.
Next, all AOIs with at least 1% of genes detected and all genes detected in at least 1% of AOIs were retained in the dataset.
Batch correction was then performed using the ComBat-Seq algorithm as implemented in the sva R package (3.52.0).
Finally, count data were normalized to the third quantile and log2-transformed for downstream analysis.
Assembly: hg38
Supplementary files format and content: DCC files: Contains target probe counts linked to one area of illumination per file with quality control metadata.
Supplementary files format and content: PKC file: Contains information regarding the Geomx Whole Transcriptome Atlas gene panel.
Supplementary files format and content: annotation_file.xlsx: Derived from lab worksheets produced from each individual run and contains relevant metadata required for analysis as published, including de-identified patient characteristics, anatomic site of origin, and time of biopsy in relation to treatment.
Supplementary files format and content: GeoMxSetObject_postQC.RDS: Third-quartile normalized and batch-corrected data object used in all downstream analysis.
Library strategy: Spatial Transcriptomics

molecule: total RNA

organism: Homo sapiens

source_name: metastatic pancreatic adenocarcinoma

extract_protocol:
Two tumor biopsies were performed on most patients. One biopsy was performed during screening and one was performed after 4-6 weeks of treatment from the same metastatic site to acquire cores for formalin-fixed, paraffin-embedded (FFPE) blocks, frozen OCT blocks, and fresh tissue studies. Slides from FFPE tissue were hematoxylin and eosin (H&E)-stained, followed by review by a pathologist. If no viable tumor was identified in FFPE cores, OCT cores were converted to FFPE blocks if available.
The GeoMx DSP libraries were prepared according to the manufacturer's instructions for the GeoMx Human Whole Transcriptome Atlas (WTA) assay.

treatment_protocol: Each treatment cycle consisted of 28 days. All patients whose samples are represented in this study received albumin-bound paclitaxel followed by gemcitabine (GA). Albumin-bound paclitaxel was administered as a 30-minute infusion at a dose of 125 mg/m2 (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30-minute infusion for three consecutive weeks followed by a week of rest (treatment on days 1, 8, and 15, during a 28-day cycle). Patients assigned to the GA plus oral placebo arm received an oral placebo taken once daily that could not be physically distinguished from the oral paricalcitol pill. Patients assigned to the GA plus intravenous (IV) paricalcitol arm were initially scheduled to receive 25 mcg of IV paricalcitol three times weekly. However, due to clinical care restrictions imposed during the COVID pandemic, the dose was reduced to 75 mcg of IV paricalcitol weekly. Only one patient received thrice weekly dosing prior to the dosing change. Patients assigned to the GA plus PO paricalcitol arm received 16 mcg of oral paricalcitol daily, which was thought to be analogous to a cumulative weekly dose as 75 mcg of IV paricalcitol based upon the bioavailability of PO paricalcitol.

tag: tissue

value: metastatic pancreatic adenocarcinoma

tag: biopsy site

value: liver

tag: segment

value: Center

tag: region of_interest_number

tag: patient id

tag: treatment

tag: biopsy timepoint

value: pre-treatment

tag: Sex

value: M

tag: race

value: White

tag: ethnicity

value: Non-Hispanic

tag: age

tag: batch


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 513
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 512
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 511
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 510
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 528
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 508
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 527
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 506
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 507
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 509
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 505
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 6

description:
Library name: Sample 504
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Gemcitabine/Nab-Paclitaxel plus Placebo

value: Black or African American


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 6

description:
Library name: Sample 502
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 6

description:
Library name: Sample 503
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 7

description:
Library name: Sample 501
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID75, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1, Slide 2

description:
Library name: Sample 497
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 500
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: omentum

value: F


title: ID75, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1, Slide 2

description:
Library name: Sample 495
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 5, Slide 2

description:
Library name: Sample 494
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 5, Slide 2

description:
Library name: Sample 493
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 498
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 518
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 5, Slide 2

description:
Library name: Sample 492
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4, Slide 2

description:
Library name: Sample 491
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4, Slide 2

description:
Library name: Sample 489
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4, Slide 2

description:
Library name: Sample 490
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3, Slide 2

description:
Library name: Sample 487
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 3, Slide 2

description:
Library name: Sample 488
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 2, Slide 2

description:
Library name: Sample 485
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2, Slide 2

description:
Library name: Sample 484
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2, Slide 2

description:
Library name: Sample 483
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1, Slide 2

description:
Library name: Sample 482
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1, Slide 2

description:
Library name: Sample 481
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 5

description:
Library name: Sample 476
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: on-treatment


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 478
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1, Slide 2

description:
Library name: Sample 480
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 6

description:
Library name: Sample 479
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID75, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1, Slide 2

description:
Library name: Sample 496
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 499
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 5

description:
Library name: Sample 474
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 473
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 470
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 469
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 472
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 468
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 465
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 463
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 467
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 3, Slide 2

description:
Library name: Sample 486
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 464
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 462
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 6

description:
Library name: Sample 459
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 460
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 5

description:
Library name: Sample 458
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 457
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 6

description:
Library name: Sample 477
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 6

description:
Library name: Sample 461
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 475
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 454
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 5

description:
Library name: Sample 456
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 4

description:
Library name: Sample 453
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 451
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 455
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 450
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 452
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 448
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 4

description:
Library name: Sample 471
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 466
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 449
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 445
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 447
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 444
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 6

description:
Library name: Sample 443
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 446
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 6

description:
Library name: Sample 441
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 442
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 5

description:
Library name: Sample 438
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 439
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 437
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 4

description:
Library name: Sample 435
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 434
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 432
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 433
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 431
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 430
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 429
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 426
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 428
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 427
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 1

description:
Library name: Sample 423
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: lung


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 2

description:
Library name: Sample 425
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 2

description:
Library name: Sample 424
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 420
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 1

description:
Library name: Sample 421
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 6

description:
Library name: Sample 419
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 5

description:
Library name: Sample 440
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 418
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 5

description:
Library name: Sample 417
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 416
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 414
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 413
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 436
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 4

description:
Library name: Sample 415
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 410
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 411
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 412
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 409
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 408
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 407
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4

description:
Library name: Sample 403
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 6

description:
Library name: Sample 405
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 406
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4

description:
Library name: Sample 404
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4

description:
Library name: Sample 402
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 1

description:
Library name: Sample 422
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3

description:
Library name: Sample 400
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 3

description:
Library name: Sample 399
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 3

description:
Library name: Sample 401
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2

description:
Library name: Sample 396
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 395
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 2

description:
Library name: Sample 398
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2

description:
Library name: Sample 397
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 392
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 394
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID91, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 393
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 389
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 387
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 390
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 391
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 388
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 385
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 381
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 384
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 383
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 380
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 382
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 379
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 378
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 7

description:
Library name: Sample 375
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 7

description:
Library name: Sample 376
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 7

description:
Library name: Sample 374
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 6

description:
Library name: Sample 373
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 377
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 372
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 370
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 5

description:
Library name: Sample 371
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 368
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 5

description:
Library name: Sample 369
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 367
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 4

description:
Library name: Sample 366
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID64, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 386
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 364
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 365
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 360
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 363
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 362
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 358
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 361
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 7

description:
Library name: Sample 356
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 359
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 6

description:
Library name: Sample 353
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 7

description:
Library name: Sample 355
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 7

description:
Library name: Sample 354
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 5

description:
Library name: Sample 351
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 6

description:
Library name: Sample 352
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 5

description:
Library name: Sample 350
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4

description:
Library name: Sample 348
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4

description:
Library name: Sample 346
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 5

description:
Library name: Sample 349
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2

description:
Library name: Sample 342
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4

description:
Library name: Sample 347
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 2

description:
Library name: Sample 343
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3

description:
Library name: Sample 344
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 340
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2

description:
Library name: Sample 341
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 3

description:
Library name: Sample 345
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Full ROI, 6

description:
Library name: Sample 337
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Full ROI


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 338
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID63, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 339
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 357
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Full ROI, 4

description:
Library name: Sample 331
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: periumbilical


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Full ROI, 4

description:
Library name: Sample 335
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Full ROI, 5

description:
Library name: Sample 336
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 329
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Full ROI, 1

description:
Library name: Sample 332
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 328
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 330
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 324
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 325
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Full ROI, 2

description:
Library name: Sample 327
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Full ROI, 1

description:
Library name: Sample 326
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 319
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 318
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 323
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Full ROI, 3

description:
Library name: Sample 334
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 315
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 321
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 312
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 317
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 313
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 316
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Full ROI, 2

description:
Library name: Sample 333
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 311
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 5, Slide 2

description:
Library name: Sample 305
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 5

description:
Library name: Sample 310
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 4, Slide 2

description:
Library name: Sample 303
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 314
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 5, Slide 2

description:
Library name: Sample 306
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 6, Slide 2

description:
Library name: Sample 307
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 6, Slide 2

description:
Library name: Sample 308
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.